Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis

Clinical Immunology

Volumn 160, Issue 2, 2015, Pages 277-281

  Shimizu, Masaki ^a   Nakagishi, Yasuo ^b   Inoue, Natsumi ^a   Mizuta, Mao ^b   Ko, Giyo ^c   Saikawa, Yutaka ^c   Kubota, Tomohiro ^d   Yamasaki, Yuichi ^d   Takei, Syuji ^d   Yachie, Akihiro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KOBE CHILDREN S HOSPITAL   (Japan)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Interleukin 18 (IL 18); Prediction of macrophage activation syndrome; Systemic juvenile idiopathic arthritis

Indexed keywords

CYCLOSPORIN; INTERLEUKIN 18; INTERLEUKIN 6; METHOTREXATE; PREDNISOLONE; TOCILIZUMAB; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE ACTIVATION SYNDROME; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; ADOLESCENT; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; IMMUNOLOGY; JUVENILE RHEUMATOID ARTHRITIS; LONGITUDINAL STUDY; PRESCHOOL CHILD; PROGNOSIS;

ADOLESCENT; ARTHRITIS, JUVENILE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INTERLEUKIN-18; INTERLEUKIN-6; LONGITUDINAL STUDIES; MACROPHAGE ACTIVATION SYNDROME; MALE; PROGNOSIS;

EID: 84938278933     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.06.005     Document Type: Article

References (52)

1. Ravelli A., Grom A.A., Behrens E.M., Cron R.Q. Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 2012, 13:289-298.
2. Mellins E.D., Macaubas C., Grom A.A. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat. Rev. Rheumatol. 2011, 7:416-426.
3. Behrens E.M., Beukelman T., Paessler M., Cron R.Q. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J. Rheumatol. 2007, 34:1133-1138.
4. Bleesing J., Prada A., Siegel D.M., Villanueva J., Olson J., Ilowite N.T., et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum. 2007, 56:965-971.
5. Sawhney S., Woo P., Murray K.J. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch. Dis. Child. 2001, 85:421-426.
6. Stéphan J.L., Koné-Paut I., Galambrun C., Mouy R., Bader-Meunier B., Prieur A.M. Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology 2001, 40:1285-1292.
7. Ramanan A.V., Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 2003, 30:401-403.
8. Ravelli A. Macrophage activation syndrome. Curr. Opin. Rheumatol. 2002, 14:548-552.
9. Grom A.A., Mellins E.D. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr. Opin. Rheumatol. 2010, 22:561-566.
10. Athreya B.H. Is macrophage activation syndrome a new entity?. Clin. Exp. Rheumatol. 2002, 20:121-123.
11. Ramanan A.V., Schneider R. Macrophage activation syndrome-what's in a name!. J. Rheumatol. 2003, 30:2513-2516.
12. Frosch M., Roth J. New insights in systemic juvenile idiopathic arthritis-from pathophysiology to treatment. Rheumatology 2008, 47:121-125.
13. de Jager W., Hoppenreijs E.P., Wulffraat N.M., Wedderburn L.R., Kuis W., Prakken B.J. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann. Rheum. Dis. 2007, 66:588-589.
14. Bruck N., Schnabel A., Hdrich C. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin. Immunol. 2015, 159:72-83.
15. Shimizu M., Yokoyama T., Yamada K., Kaneda H., Wada H., Wada T., et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology (Oxford) 2010, 49:1645-1653.
16. Put K., Avau A., Brisse E., Mitera T., Put S., Proost P., et al. Cytokines in systemic juvenile idiopathic arthritis and haemophagocytic lymphohistiocytosis: tipping the balance between interleukin-18 and interferon γ. Rheumatology 2015, (in press).
17. Shigemura T., Yamazaki T., Hara Y., Ou J.N., Stevens A.M., Ochs H.D., et al. Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome. Pediatr. Rheumatol. Online J. 2011, 9:15.
18. Shimizu M., Nakagishi Y., Yachie A. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. Cytokine 2013, 61:345-348.
19. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton. J. Rheumatol. 2001, 31:390-392.
20. Ravelli A., Magni-Manzoni S., Pistorio A., Besana C., Foti T., Ruperto N., et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J. Pediatr. 2005, 46:598-604.
21. Macaubas C., Nguyen K., Deshpande C., Phillips C., Peck A., Lee T., et al. Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin. Immunol. 2010, 134:206-216.
22. Macaubas C., Nguyen K.D., Peck A., Buckingham J., Deshpande C., Wong E., et al. Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin. Immunol. 2012, 142:362-372.
23. Shimizu M., Yachie A. Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages. Cytokine 2012, 60:226-232.
24. Martinez F., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front. Biosci. 2008, 13:453-461.
25. Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006.
26. Verbsky J.W., White A.J. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 2004, 31:2071-2075.
27. Ruperto N., Brunner H.I., Quartier P., Constantin T., Wulffraat N., Horneff G., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012, 367:2396-2406.
28. Gattorno M., Piccini A., Lasiglie D., Tassi S., Brisca G., Carta S., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008, 58:1505-1515.
29. Shimizu M., Nakagishi Y., Kasai K., Yamasaki Y., Miyoshi M., Takei S., et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine 2012, 58:287-294.
30. Fitzgerald A.A., Leclercq S.A., Yan A., Homik J.E., Dinarello C.A. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005, 52:1794-1803.
31. Kawashima M., Yamamura M., Taniai M., Yamauchi H., Tanimoto T., Kurimoto M., et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum. 2005, 52:1794-1803.
32. Kawaguchi Y., Terajima H., Harigai M., Hara M., Kamatani N. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum. 2001, 44:1716-1717.
33. Cabane J., Michon A., Ziza J.M., Bourgeois P., Blétry O., Godeau P., et al. Comparison of long term evolution of adult onset and juvenile onset Still's disease, both followed up for more than 10years. Ann. Rheum. Dis. 1990, 49:283-285.
34. Ichida H., Kawaguchi Y., Sugiura T., Takagi K., Katsumata Y., Gono T., et al. Clinical manifestations of adult-onset Still's disease presenting with erosive arthritis: association with low levels of ferritin and interleukin-18. Arthritis Care Res. 2014, 66:642-646.
35. Okamura H., Nagata K., Komatsu T., Tanimoto T., Nukata Y., Tanabe F., et al. A novel costimulatory factor for gamma interferon induction found in the livers of mice causes endotoxic shock. Infect. Immun. 1995, 63:3966-3972.
36. Okamura H., Tsutsi H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., et al. Cloning of a new cytokine that induces IFN-g production by T cells. Nature 1995, 378:88-91.
37. Gracie J.A., Robertson S.E., McInnes I.B. Interleukin-18. J. Leukoc. Biol. 2003, 73:213-224.
38. Gracie J.A. Interleukin-18 as a potential target in inflammatory arthritis. Clin. Exp. Immunol. 2004, 136:402-404.
39. Yoshimoto T., Tsutsui H., Tominaga K., Hoshino K., Okamura H., Akira S., et al. IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:13962-13966.
40. Maeno N., Takei S., Nomura Y., Imanaka H., Hokonohara M., Miyata K. Highly elevated serum concentrations of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. Arthritis Rheum. 2002, 46:2539-2541.
41. Adachi O., Kawai T., Takeda K., Matsumoto M., Tsutsui H., Sakagami M., et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 1998, 9:143-150.
42. Okamura H., Kashiwamura S., Tsutsui H., Yoshimoto T., Nakanishi K. Regulation of interferon-gamma production by IL-12 and IL-18. Curr. Opin. Immunol. 1998, 10:259-264.
43. Villanueva J., Lee S., Giannini E.H., Graham T.B., Passo M.H., Filipovich A., et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res. Ther. 2005, 7:R30-R37.
44. Grom A.A., Villanueva J., Lee S., Goldmuntz E.A., Passo M.H., Filipovich A Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J. Pediatr. 2003, 142:292-296.
45. Grom A.A. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?. Arthritis Rheum. 2004, 50:689-698.
46. de Jager W., Vastert S.J., Beekman J.M., Wulffraat N.M., Kuis W., Coffer P.J., et al. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2009, 60:2782-2793.
47. Gracie J.A. Interleukin-18 as a potential target in inflammatory arthritis. Clin. Exp. Immunol. 2004, 136:402-404.
48. Shimizu M., Sakakibara Y., Kawano M., Yachie A. Transient impairment of NK cell function in an infant born to a mother with adult-onset Still's disease: perinatal effect of maternal IL-18. Clin. Immunol. 2012, 143:273-274.
49. Strippoli R., Carvello F., Scianaro R., De Pasquale L., Vivarelli M., Petrini S., et al. Amplification of the response to toll-like receptor ligands by prolonged exposure to interleukin-6 in mice. Arthritis Rheum. 2012, 64:1680-1688.
50. Yokota S., Imagawa T., Mori M., Miyamae T., Takei S., Iwata N., et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J. Rheumatol. 2014, 41:759-767.
51. Ravelli A., Schneider R., Weitzman S., Devlin C., Daimaru K., Yokota S., et al. A56: macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. Arthritis Rheum. 2014, 66:S83-S84.
52. Canna S.W., de Jesus A.A., Gouni S., Brooks S.R., Marrero B., Liu Y., et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat. Genet. 2014, 46:1140-1146.